Related Experiment Videos
Anaplastic thyroid cancer
1Faculty of Medicine, Department of Surgery, Division of General Surgery, University of Calgary, Alberta, Canada. janice.pasieka@calgaryhealthregion.ca
Current Opinion in Oncology
|December 20, 2002
Summary
Anaplastic thyroid carcinoma is an aggressive cancer with a poor prognosis and limited survival. Multimodal therapy, including surgery, radiation, and chemotherapy, offers potential for long-term survival in select cases.
Area of Science:
- Oncology
- Endocrinology
- Surgical Oncology
Background:
- Anaplastic thyroid carcinoma (ATC) is a rare but highly aggressive malignancy.
- It accounts for only 2% of thyroid cancers but has a median survival limited to months.
- Most patients present with advanced disease, often with distant metastases.
Purpose of the Study:
- To summarize the current understanding of anaplastic thyroid carcinoma.
- To highlight the challenges in managing this aggressive cancer.
- To emphasize the potential role of multimodal therapy and clinical trials.
Main Methods:
- Review of existing literature on anaplastic thyroid carcinoma.
- Analysis of patient demographics and treatment outcomes.
- Evaluation of preclinical data from cell line studies.
Main Results:
- Complete surgical resection is often not feasible in ATC.
- A subset of patients with resectable disease achieved long-term survival with multimodal therapy.
- Preclinical studies suggest promise for novel therapeutic approaches.
Conclusions:
- Anaplastic thyroid carcinoma remains a challenging malignancy with a poor prognosis.
- Multimodal therapy combining surgery, radiation, and chemotherapy may improve outcomes in select patients.
- Enrollment in clinical trials for novel treatments is recommended for all ATC patients.